{
    "clinical_study": {
        "@rank": "46",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 07, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04333225"
        },
        "id_info": {
            "org_study_id": "020-132",
            "nct_id": "NCT04333225"
        },
        "brief_title": "Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers",
        "official_title": "A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baylor Research Institute",
                "agency_class": "Other"
            }
        },
        "source": "Baylor Research Institute",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "Yes",
            "is_fda_regulated_device": "No",
            "is_us_export": "No"
        },
        "brief_summary": {
            "textblock": "In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks\n      in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with\n      high risk exposure to patients infected with COVID-19 will be tested for COVID-19 infection\n      via nasopharyngeal (NP) swab once weekly for 7 weeks. Of those, one hundred eighty (180) will\n      receive weekly doses of hydroxychloroquine for the duration of the study. Subjects who opt\n      not to receive the study drug will form the control group."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 3, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "July 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "July 30, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Non-Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Prevention",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Rate of COVID-19 positive conversion",
            "time_frame": "7 weeks",
            "description": "Rate of COVID-19 positive conversion on weekly nasopharyngeal (NP) sampling"
        },
        "secondary_outcome": {
            "measure": "Time-to-first clinical event",
            "time_frame": "7 weeks",
            "description": "Time-to-first clinical event consisting of a persistent change for any of the following:\nOne positive NP sample\nCommon clinical symptoms of COVID-19 infection including fever, cough, and shortness of breath\nLess common signs and symptoms of COVID-19 infection including headache, muscle pain, abdominal pain, sputum production, and sore throat"
        },
        "other_outcome": {
            "measure": "Time-to-first clinical worsening event",
            "time_frame": "7 weeks",
            "description": "Time-to-first clinical worsening event consisting of any of the following:\nHospitalization for COVID-19 infection\nIntensive care unit admission for COVID-19 infection\nAll cause death"
        },
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "360"
        },
        "condition": "COVID-19",
        "arm_group": [
            {
                "arm_group_label": "Treatment",
                "arm_group_type": "Experimental",
                "description": "Oral hydroxychloroquine 400 mg twice a day (two 200 mg tabs twice a day) on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks."
            },
            {
                "arm_group_label": "Control",
                "arm_group_type": "No Intervention",
                "description": "Subjects who opt not to receive the study drug will undergo all procedures to form the control group"
            }
        ],
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Hydroxychloroquine",
            "description": "Weekly treatment in individuals at high risk",
            "arm_group_label": "Treatment"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult male and female healthcare workers \u2265 18 to \u2264 75 years of age upon study consent\n\n          2. Healthcare workers with\n\n             \u2022 One day or more of exposure to suspect and/or positive COVID-19 patients, including\n             but not limited to those working in the Emergency Department or Intensive Care Unit.\n\n             OR\n\n             \u2022 Unprotected exposure to a known positive COVID-19 patient within 72 hours of\n             screening.\n\n          3. Afebrile with no constitutional symptoms\n\n          4. Willing and able to comply with scheduled visits, treatment plan, and other study\n             procedures\n\n          5. Evidence of a personally signed and dated informed consent document indicating that\n             the subject (or a legally acceptable representative) has been informed of all\n             pertinent aspects of the study prior to initiation of any subject-mandated procedures\n\n        Exclusion Criteria:\n\n          1. Participation in other investigational clinical trials for the treatment or prevention\n             of SARS-COV-2 infection within 30days\n\n          2. Unwilling to practice acceptable methods of birth control (both males who have\n             partners of childbearing potential and females of childbearing potential) during\n             Screening, while taking study drug, and for at least 30 days after the last dose of\n             study drug is ingested Note: the following criteria follow standard clinical practice\n             for FDA approved indications of this medication\n\n          3. Having a prior history of blood disorders such as aplastic anemia, agranulocytosis,\n             leukopenia, or thrombocytopenia\n\n          4. Having a prior history of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency\n\n          5. Having dermatitis, psoriasis or porphyria\n\n          6. Taking Digoxin, Mefloquine, methotrexate, cyclosporine, praziquantel, antacids and\n             kaolin, cimetidine, ampicillin, Insulin or antidiabetic drugs, arrhythmogenic drugs,\n             antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas,\n             amphotericin B, high dose corticosteroids, and proton pump inhibitors, neostigmine,\n             praziquantel, Pyridostigmine, tamoxifen citrate\n\n          7. Allergies: 4-Aminoquinolines\n\n          8. Pre-existing retinopathy of the eye\n\n          9. Has a chronic liver disease or cirrhosis, including hepatitis B and/or untreated\n             hepatitis\n\n         10. Untreated or uncontrolled active bacterial, fungal infection\n\n         11. Known or suspected active drug or alcohol abuse, per investigator judgment\n\n         12. Women who are pregnant or breastfeeding\n\n         13. Known hypersensitivity to any component of the study drug\n\n         14. A known history of prolonged QT syndrome or history of additional risk factors for\n             torsades de pointe (e.g., heart failure, requires a lab test , family history of Long\n             QT Syndrome), or the use of concomitant medications that prolong the QT/QTc interval"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "75 Years",
            "healthy_volunteers": "Accepts Healthy Volunteers"
        },
        "overall_official": {
            "last_name": "Peter A McCullough, MD, MPH",
            "role": "Principal Investigator",
            "affiliation": "Baylor Health Care System"
        },
        "overall_contact": {
            "last_name": "Laura Clariday, CCRC",
            "phone": "214-820-7224",
            "email": "Laura.Clariday@BSWHealth.org"
        },
        "overall_contact_backup": {
            "last_name": "Rebecca Baker, MSN, APRN",
            "phone": "214-820-7965",
            "email": "Rebecca.Baker2@BSWHealth.org"
        },
        "location": {
            "facility": {
                "name": "Baylor University Medical Center",
                "address": {
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75226",
                    "country": "United States"
                }
            },
            "status": "Recruiting",
            "contact": {
                "last_name": "Laura Clariday, CCRC",
                "phone": "214-820-7224",
                "email": "Laura.Clariday@BSWHealth.org"
            },
            "contact_backup": {
                "last_name": "Rebecca Baker, MSN, APRN",
                "phone": "214-820-7965",
                "email": "Rebecca.Baker2@BSWHealth.org"
            },
            "investigator": {
                "last_name": "Peter A McCullough, MD, MPH",
                "role": "Principal Investigator"
            }
        },
        "location_countries": {
            "country": "United States"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 1, 2020",
        "study_first_submitted_qc": "April 2, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 3, 2020"
        },
        "last_update_submitted": "April 5, 2020",
        "last_update_submitted_qc": "April 5, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 7, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": "hydroxychloroquine",
        "condition_browse": {
            "mesh_term": "Infection"
        },
        "intervention_browse": {
            "mesh_term": "Hydroxychloroquine"
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}